About Vitadio
Vitadio is a pioneering company in the field of prescription digital therapeutics, focused on reversing insulin resistance through AI-driven lifestyle modifications.
They provide digital therapies targeting the root causes of chronic conditions, not just the symptoms, empowering people to restore their cardiometabolic health, specifically targeting type 2 diabetes and prediabetes.
Mission and Vision
Vitadio aims to create habit-building digital therapies with personalized goals, smart nudges, and evidence-based content combined with complex user data, offering real-time AI-driven feedback similar to a human dietitian available anytime and anywhere.
The company also provides proactive human support, including personal dietitians and a social network feature within the app.
Their digital therapeutics have clinically proven outcomes comparable to modern antidiabetic drugs, helping patients achieve recommended HbA1c levels and significant weight reduction.
Vitadio operates with headquarters in Prague and Berlin and serves multiple European countries with ongoing expansion efforts.
Vitadio is certified as a Class I medical device under MDR and complies with ISO 27001, ISO 13485, and GDPR standards.
Additional Information
The company collaborates with leading pharmaceutical players like AstraZeneca and Novo Nordisk, augmenting pharmacotherapy with their digital therapeutics for improved patient outcomes.
Their digital therapy for type 2 diabetes is covered by all statutory health insurers in Germany.
Vitadio has been featured in various respected media, including Forbes, CT, Die Welt, Bild, and Handelsblatt.
Currently, their mobile app is available in Czech, Italian, and German languages.